Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX295 in Advanced Solid Tumors
NCT03975387Phase 1Terminated
- Sponsor
- Taiho Oncology
- Start
- Jul 2019
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of astx295 in solid tumor, sponsored by Taiho Oncology. Primary endpoints: Safety and tolerability of ASTX295 including determination of maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE), Recommended Phase 2 Dose and 2 more. Started Jul 2019; status: terminated.
02
Drugs
astx295
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03975387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03975387.